132 related articles for article (PubMed ID: 34562615)
1. Predicted Immunogenicity of CDK12 Biallelic Loss-of-Function Tumors Varies across Cancer Types.
Elliott A; Zhang J; Zhang Q; Swensen J; Martin D; Xiu J; Geynisman DM; Vaena D; Herzog TJ; Holloway RW; El-Deiry WS; Spetzler D; Heath E; Stafford P; Korn WM
J Mol Diagn; 2021 Dec; 23(12):1761-1773. PubMed ID: 34562615
[TBL] [Abstract][Full Text] [Related]
2. Pan-Cancer Analysis of
Sokol ES; Pavlick D; Frampton GM; Ross JS; Miller VA; Ali SM; Lotan TL; Pardoll DM; Chung JH; Antonarakis ES
Oncologist; 2019 Dec; 24(12):1526-1533. PubMed ID: 31292271
[TBL] [Abstract][Full Text] [Related]
3. Inactivation of CDK12 Delineates a Distinct Immunogenic Class of Advanced Prostate Cancer.
Wu YM; Cieślik M; Lonigro RJ; Vats P; Reimers MA; Cao X; Ning Y; Wang L; Kunju LP; de Sarkar N; Heath EI; Chou J; Feng FY; Nelson PS; de Bono JS; Zou W; Montgomery B; Alva A; ; Robinson DR; Chinnaiyan AM
Cell; 2018 Jun; 173(7):1770-1782.e14. PubMed ID: 29906450
[TBL] [Abstract][Full Text] [Related]
4. Clinical Outcomes in Cyclin-dependent Kinase 12 Mutant Advanced Prostate Cancer.
Reimers MA; Yip SM; Zhang L; Cieslik M; Dhawan M; Montgomery B; Wyatt AW; Chi KN; Small EJ; Chinnaiyan AM; Alva AS; Feng FY; Chou J
Eur Urol; 2020 Mar; 77(3):333-341. PubMed ID: 31640893
[TBL] [Abstract][Full Text] [Related]
5. Pan-cancer Analysis of CDK12 Alterations Identifies a Subset of Prostate Cancers with Distinct Genomic and Clinical Characteristics.
Nguyen B; Mota JM; Nandakumar S; Stopsack KH; Weg E; Rathkopf D; Morris MJ; Scher HI; Kantoff PW; Gopalan A; Zamarin D; Solit DB; Schultz N; Abida W
Eur Urol; 2020 Nov; 78(5):671-679. PubMed ID: 32317181
[TBL] [Abstract][Full Text] [Related]
6. Analysis of CDK12 alterations in a pan-cancer database.
Pan E; Cabal A; Javier-DesLoges J; Patel D; Panian J; Lee S; Shaya J; Nonato T; Xu X; Stewart T; Rose B; Shabaik A; Cohen E; Kurzrock R; Tamayo P; McKay RR
Cancer Med; 2022 Feb; 11(3):753-763. PubMed ID: 34898046
[TBL] [Abstract][Full Text] [Related]
7.
Warner E; Herberts C; Fu S; Yip S; Wong A; Wang G; Ritch E; Murtha AJ; Vandekerkhove G; Fonseca NM; Angeles A; Beigi A; Schönlau E; Beja K; Annala M; Khalaf D; Chi KN; Wyatt AW
Clin Cancer Res; 2021 Mar; 27(6):1650-1662. PubMed ID: 33414135
[TBL] [Abstract][Full Text] [Related]
8.
Lotan TL; Antonarakis ES
Clin Cancer Res; 2021 Jan; 27(2):380-382. PubMed ID: 33199495
[TBL] [Abstract][Full Text] [Related]
9. Ovarian Cancers Harboring Inactivating Mutations in CDK12 Display a Distinct Genomic Instability Pattern Characterized by Large Tandem Duplications.
Popova T; Manié E; Boeva V; Battistella A; Goundiam O; Smith NK; Mueller CR; Raynal V; Mariani O; Sastre-Garau X; Stern MH
Cancer Res; 2016 Apr; 76(7):1882-91. PubMed ID: 26787835
[TBL] [Abstract][Full Text] [Related]
10. Characterizing cyclin-dependent kinase 12(CDK12)-altered aggressive prostate cancer: a twelve-case series.
Iwasawa T; Kosaka T; Yasumizu Y; Hongo H; Yanai Y; Baba Y; Matsumoto K; Nakamura K; Nishihara H; Oya M
Int J Clin Oncol; 2022 Dec; 27(12):1867-1873. PubMed ID: 36271301
[TBL] [Abstract][Full Text] [Related]
11. CDK12 inactivation across solid tumors: an actionable genetic subtype.
Marshall CH; Imada EL; Tang Z; Marchionni L; Antonarakis ES
Oncoscience; 2019 May; 6(5-6):312-316. PubMed ID: 31360735
[TBL] [Abstract][Full Text] [Related]
12. CDK12: an emerging therapeutic target for cancer.
Lui GYL; Grandori C; Kemp CJ
J Clin Pathol; 2018 Nov; 71(11):957-962. PubMed ID: 30104286
[TBL] [Abstract][Full Text] [Related]
13. Alteration in TET1 as potential biomarker for immune checkpoint blockade in multiple cancers.
Wu HX; Chen YX; Wang ZX; Zhao Q; He MM; Wang YN; Wang F; Xu RH
J Immunother Cancer; 2019 Oct; 7(1):264. PubMed ID: 31623662
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of CDK12 Protein Expression as a Potential Novel Biomarker for DNA Damage Response-Targeted Therapies in Breast Cancer.
Naidoo K; Wai PT; Maguire SL; Daley F; Haider S; Kriplani D; Campbell J; Mirza H; Grigoriadis A; Tutt A; Moseley PM; Abdel-Fatah TMA; Chan SYT; Madhusudan S; Rhaka EA; Ellis IO; Lord CJ; Yuan Y; Green AR; Natrajan R
Mol Cancer Ther; 2018 Jan; 17(1):306-315. PubMed ID: 29133620
[TBL] [Abstract][Full Text] [Related]
15. CDK12 regulates DNA repair genes by suppressing intronic polyadenylation.
Dubbury SJ; Boutz PL; Sharp PA
Nature; 2018 Dec; 564(7734):141-145. PubMed ID: 30487607
[TBL] [Abstract][Full Text] [Related]
16. [Function of CDK12 in Tumor initiation and progression and its clinical consequences].
Vrábel D; Svoboda M; Navrátil J; Kohoutek J
Klin Onkol; 2014; 27(5):340-6. PubMed ID: 25312711
[TBL] [Abstract][Full Text] [Related]
17. Characterizing CDK12-Mutated Prostate Cancers.
Rescigno P; Gurel B; Pereira R; Crespo M; Rekowski J; Rediti M; Barrero M; Mateo J; Bianchini D; Messina C; Fenor de la Maza MD; Chandran K; Carmichael J; Guo C; Paschalis A; Sharp A; Seed G; Figueiredo I; Lambros M; Miranda S; Ferreira A; Bertan C; Riisnaes R; Porta N; Yuan W; Carreira S; de Bono JS
Clin Cancer Res; 2021 Jan; 27(2):566-574. PubMed ID: 32988971
[TBL] [Abstract][Full Text] [Related]
18. Identification and Utilization of Biomarkers to Predict Response to Immune Checkpoint Inhibitors.
Gjoerup O; Brown CA; Ross JS; Huang RSP; Schrock A; Creeden J; Fabrizio D; Tolba K
AAPS J; 2020 Oct; 22(6):132. PubMed ID: 33057937
[TBL] [Abstract][Full Text] [Related]
19.
Tien JC; Chang Y; Zhang Y; Chou J; Cheng Y; Wang X; Yang J; Mannan R; Shah P; Wang XM; Todd AJ; Eyunni S; Cheng C; Rebernick RJ; Xiao L; Bao Y; Neiswender J; Brough R; Pettitt SJ; Cao X; Miner SJ; Zhou L; Wu YM; Labanca E; Wang Y; Parolia A; Cieslik M; Robinson DR; Wang Z; Feng FY; Lord CJ; Ding K; Chinnaiyan AM
bioRxiv; 2024 Mar; ():. PubMed ID: 38562774
[TBL] [Abstract][Full Text] [Related]
20. Th e role of CDK12 in tumor bio logy.
Dzimková M; Procházková J; Klát J; Kohoutek J
Klin Onkol; 2020; 33(4):260-267. PubMed ID: 32894954
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
